{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106525","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.389061+00:00","generated_at":"2026-05-17T15:10:08.012552+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gyre Therapeutics Q2 revenue $26.8M (+6% YoY); net income falls to $1.6M; CEO transition","bullets":["GAAP net income of $1.6M ($0.00 EPS) vs $4.5M in Q2 2024; H1 net income $5.3M vs $14.5M.","Revenue Q2 $26.8M, up from $25.2M; H1 $48.8M, down from $52.4M due to ETUARY decline and new product launches.","Full-year revenue guidance reaffirmed at $118-128M (11-21% growth). Non-GAAP adj. net income Q2 $2.9M vs $3.1M.","CEO Han Ying resigned, becomes SVP Science; Executive Chair Ping Zhang appointed interim CEO.","Pipeline: Positive Phase 3 Hydronidone data; NDA filing with NMPA expected Q3 2025. Launched Etorel in June."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106525","json":"https://secwatch.observer/filing/0000950170-25-106525.json","markdown":"https://secwatch.observer/filing/0000950170-25-106525.md","text":"https://secwatch.observer/filing/0000950170-25-106525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000095017025106525/0000950170-25-106525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000095017025106525/gyre-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:10:08.012552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}